IP Library Granted Patent US 8,048,853
Granted Patent B2
US 8,048,853 · App. 12/138,488 · Granted Nov 1, 2011

Process for preparing pharmaceutical compound and intermediates thereof

Assignee: Xellia Pharmaceuticals APS
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,048,853
App. No.
12/138,488
Granted
Nov 1, 2011
Kind
B2
Abstract

The present invention relates to novel intermediates of formula VII, or an acid addition salt or a solvate thereof, wherein R 1 is —(CO)NH 2 , —CH 2 NH 2 or —CN; R 2 =R 3 =H or R 2 and R 3 together form a cyclic boronate or borate ester; X is a helping group selected from the group consisting of i) a five or six membered heterocyclic aromatic ring and derivatives thereof comprising at least one N-atom being a part of an imine-group, wherein said N-atom forms the point of connection to the cyclohexapeptide ring, and ii) tetrazolyl and derivatives thereof for which a nitrogen atom forms the point of connection to the cyclohexapeptide ring, and a process for the preparation of caspofungin utilizing said intermediates.

Claims (33)

1. Compounds of formula VII

or an acid addition salt thereof, wherein R 1 is —(CO)NH 2 , —CH 2 NH 2 or —CN;

R 2 =R 3 =H or R 2 and R 3 together form a cyclic boronate or borate ester;

X is a helping group selected from the group consisting of i) a five or six membered heterocyclic aromatic ring comprising at least one N-atom being a part of an imine-group, wherein said N-atom forms the point of connection to the cyclohexapeptide ring, and ii) tetrazolyl for which a nitrogen atom forms the point of connection to the cyclohexapeptide ring.

2. Compound according to claim 1 , wherein R 1 is —CH 2 NH 2 .

3. Compound of the formula V or V′

or an acid addition salt thereof, wherein R 1 is —(CO)NH 2 , —CH 2 NH 2 or —CN.

4. Compound according to claim 3 wherein R 1 is —CH 2 NH 2 .

5. Compound of the formula (VI)

or an acid addition salt thereof, wherein R 1 is —(CO)NH 2 , —CH 2 NH 2 or —CN.

6. Compound according to claim 5 wherein R 1 is —CH 2 NH 2 or an acid addition salt thereof.

7. The process of producing a compound of formula VIII

or a pharmaceutically acceptable salt thereof comprising the steps of

a) reacting a compound of formula VII or an acid addition salt thereof

wherein R 1 is —(CO)NH 2 , —CH 2 NH 2 or —CN;

R 2 =R 3 =H or R 2 and R 3 together form a cyclic boronate or borate ester;

X is a helping group selected from the group consisting of i) a five or six membered heterocyclic aromatic ring comprising at least one N-atom being a part of an imine-group, wherein said N-atom forms the point of connection to the cyclohexapeptide ring, and ii) tetrazolyl for which a nitrogen atom forms the point of connection to the cyclohexapeptide ring, with 1,2-diaminoethane to obtain a compound of formula VIII or a pharmaceutically acceptable salt thereof

and

b) optionally isolating the compound of formula VIII or a pharmaceutically acceptable salt thereof as obtained in step a).

8. The process of producing caspofungin (I)

or a pharmaceutically acceptable salt thereof comprising the steps of

a) reacting the compound of formula IX or an acid addition salt thereof

wherein R 1 is —(CO)NH 2 , —CH 2 NH 2 or —CN with i) a five or six membered heterocyclic aromatic compound comprising at least one N-atom being a part of an imine-group, or ii) tetrazole

to form a compound of formula VII

wherein R 1 and X are as defined above;

R 2 =R 3 =H or R 2 and R 3 together form a cyclic boronate or borate ester;

b) followed by substituting X with 1,2-diaminoethane to give a compound of formula VIII or a pharmaceutically acceptable salt thereof

c) optionally isolating the compound of formula I or a pharmaceutically acceptable salt thereof, provided that if R 1 in formula IX is —(CO)NH 2 or —CN a reduction is performed before or after step a) or b), respectively to afford the compound of formula I as the final product.

9. A process according to claim 8 wherein step a) to c), including the reduction of R 1 , are performed as a one-pot telescoped process.

10. A process according to claim 8 wherein X is introduced in reaction with pyridine and the compound of formula VII is

or an acid addition salt thereof.

11. A process according to claim 8 wherein X is introduced in reaction with tetrazole and the compound of formula VII is

or an acid addition salt thereof.

Assignments (3)
CHANGE OF NAME Recorded Nov 3, 2010
From: AXELLIA PHARMACEUTICALS APS
To: XELLIA PHARMACEUTICALS APS
Reel/Frame 025237/0789 →
CHANGE OF NAME Recorded Sep 29, 2008
From: ALPHARMA APS
To: AXELLIA PHARMACEUTICALS APS
Reel/Frame 021597/0161 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 22, 2008
From: HEGGELUND, AUDUN; KVERNENES, OLE HEINE; BJORNSTAD, VIDAR
To: ALPHARMA APS
Reel/Frame 021426/0383 →
Continuity (1)
Related Publication 20090312541A1 · Dec 17, 2009